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Accepted 7 April 2015The worldwide growth in the incidence of gastrointestinal disorders has created an
immediate need to identify safe and effective interventions. In this randomized, double-
blind, placebo-controlled study, we examined the effects of Actazin and Gold, kiwifruit-
derived nutritional ingredients, on stool frequency, stool form, and gastrointestinal comfort
in healthy and functionally constipated (Rome III criteria for C3 functional constipation)
individuals. Using a crossover design, all participants consumed all 4 dietary interventions
(Placebo, Actazin low dose [Actazin-L] [600 mg/day], Actazin high dose [Actazin-H] [2400
mg/day], and Gold [2400 mg/day]). Each intervention was taken for 28 days followed by a 14-
day washout period between interventions. Participants recorded their daily bowel
movements and well-being parameters in daily questionnaires. In the healthy cohort (n =
19), the Actazin-H (P = .014) and Gold (P = .009) interventions significantly increased the
mean daily bowel movements compared with the washout. No significant differences were
observed in stool form as determined by use of the Bristol stool scale. In a subgroup analysis
of responders in the healthy cohort, Actazin-L (P = .005), Actazin-H (P < .001), and Gold (P =
.001) consumption significantly increased the number of daily bowel movements by greater
than 1 bowel movement per week. In the functionally constipated cohort (n = 9), there were
no significant differences between interventions for bowel movements and the Bristol stool
scale values or in the subsequent subgroup analysis of responders. This study
demonstrated that Actazin and Gold produced clinically meaningful increases in bowel
movements in healthy individuals.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Gastrointestinal issues, including constipation, are common
conditions worldwide in adults and children [1,2], which can
severely affect the individual's quality of life and feeling of
general well-being. Factors such as sex, aging, socioeconomic
status, and educational level can affect the prevalence of
constipation worldwide [2]. The intervention options for
constipation remain difficult and challenging, and many
individuals are dissatisfied with current therapies and med-
ication. The current interventions for constipation include
lifestyle and dietary modifications as well as pharmacologic
interventions with stool softeners, osmotic laxatives, and
stimulant laxatives. The worldwide growth in the incidence of
gastrointestinal disorders has created an immediate need to
identify safe and effective interventions.
A food-based approach to prevent constipation can be
considered as an effective long-term solution [3]. Food
ingredients such as psyllium and wheat bran are the most
studied for preventing constipation. It is generally regarded
that adequate intakes of fiber-rich fruits and vegetables daily
with sufficient water prevent the incidences of constipation.
Green kiwifruit are excellent sources of vitamins (A, C, and E),
minerals (potassium), dietary fiber, and polyphenols [4].
Whole kiwifruit consumption has been shown to have
beneficial effects on constipation, with several clinical studies
demonstrating its efficacy [5] by improving laxation in
healthy individuals [6,7] and in patients with irritable bowel
syndrome with constipation [8]. It is thought that the unique
combination of soluble and insoluble fibers; polyphenols; and
the enzyme, actinidin, present in kiwifruit confers this and
other health benefits.
Actazin and Gold are powdered ingredients derived from
whole New Zealand green (Actinidia deliciosa “Hayward”) and
gold (Actinidia chinensis “Zesy002”) kiwifruit from which the
skin and seeds are removed and the remaining flesh cold
processed for use in food and dietary supplements. We
hypothesized that kiwifruit components present in Actazin
and Gold improve stool frequency, stool form, and gastroin-
testinal comfort in healthy and constipated individuals (Rome
III criteria for C3 functional constipation).2. Methods and materials
2.1. Participants
The participants were recruited through newspaper and radio
advertisements; community, local district health board, and
tertiary institution newsletters; posters in doctors' general
practice surgeries; and through our existing database of past
participants. Participants were selected if they were aged 18 to
60 years, had a bodymass index (BMI) between 19 and 30 kg/m2,
and fasting blood glucose less than 5.6 mmol/L. Participants
were excluded if there were gastrointestinal alarm symptoms
present (including blood in stools, frequent diarrhea, and
unremitting abdominal pain); they were following a vegan,
raw food, or very high-fiber diet (recommended fiber intake of
25-28 g/day for women and 30-38 g/day for men); hadgastroparesis or lactose intolerance; surgery for weight loss
(lap band or gastric bypass); clinically significant renal, hepatic,
endocrine, cardiac, pulmonary, pancreatic, neurologic, hema-
tologic, or biliary disorders as disclosed or detected through the
comprehensive metabolic panel (Chem-20) taken at the initial
screening visit; were pregnant; or had a known allergy or
sensitivity to kiwifruit.
The subjects were asked to exclude high-fiber dietary
supplements such as Metamucil, Benefibre, and Phloe to
maintain their habitual food and beverage intakes and
physical activity patterns as well as to refrain from eating
fresh kiwifruit for the study period. They were also asked to
avoid overseas travel for the period of the study because of the
impact this may have on diet. Venous blood samples (~10 mL)
were collected at the beginning and end of the study for
biochemical analysis (Chem-20).
2.2. Study design
The study was a randomized, double-blind, placebo-
controlled, crossover trial. Participants were recruited from
Christchurch, New Zealand, into 2 cohorts (Figure): healthy
participants who had no clinical symptoms of constipation
and functionally constipated participants who met the Rome
III criteria for C3 functional constipation [9] at recruitment.
The Rome III criteria for C3 functional constipation includes 2
or more of the following: straining during at least 25% of
defecations, lumpy or hard stools in at least 25% defecations,
a sensation of anorectal obstruction or blockage for at least
25% defecations, sensation of incomplete evacuation for at
least 25% defecations, manual maneuvers to facilitate at least
25% defecations, 3 or fewer defecations per week, loose stools
rarely present without the use of laxatives, and insufficient
criteria for irritable bowel syndrome.
Before the start of the study, there was a 14-day washout
period to establish baseline measurements. All participants
then consumed 4 dietary interventions each for 28 days, with a
14-day washout period between interventions. The washout
period of 2 weeks was chosen to allow sufficient time to return
bowel habits to baseline for the parameters measured. The
dietary interventions were placebo (isomalt), Actazin low dose
(Actazin-L) (600 mg/day), Actazin high dose (Actazin-H)
(2400 mg/day), and Gold (2400 mg/day). The interventions
were delivered in 4 × 600 mg capsules (Table 1) manufactured
to appear the same tomaintain intervention blinding and were
supplied by Anagenix Ltd (Wellington, New Zealand). The
intervention was taken in the morning with a glass of water.
Nutritional information for the Actazin and Gold powders is
presented in Table 2. The Gold powder contained no additional
ingredients, whereas the Actazin powder contained silica and
microcrystalline cellulose (<7.5%). The personnel recruiting
participants were blinded to the order of interventions and the
intervention identifications. The order in which participants
were allocated their intervention was randomized by a biostat-
istician using a Williams Latin square design and computer-
generated random numbers. Upon completion of the analyses,
the study was unblinded to reveal the intervention order.
Participants completed a 3-day food diary at the beginning
and end of the trial to assess their normal dietary intake.
Participants recorded their daily bowel movements and well-
Figure – Recruitment flow chart of participants in the healthy and functionally constipated cohorts. Recruitment into the
functionally constipated cohort proved challenging, with the primary reasons for not participating being preexisting medical
conditions, the length of the study, and the requirement to refrain from eating fresh kiwifruit for the study duration.
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questions about numbers of bowel movements; incomplete
and assisted bowel movements; assessment of stools on the
Bristol stool scale [11]; and about bloating, flatulence, laxa-
tives, and abdominal pain. For the Bristol stool score, where
several stools may be evaluated per day, a mean score per day
was calculated and then a mean of the daily means. The
Bristol stool score was evaluated visually, scoring was from 1
(hard to pass) to 7 (entirely liquid).
This study was conducted according to guidelines laid
down in the Declaration of Helsinki, and all procedures
involving human subjects were approved by the New Zealand
Human Disability and Ethics Committee (12/STH/72/AM01).
Written informed consent was obtained from all participants.
The trial was registered with the Australia New Zealand
Clinical Trials Registry (ACTRN: 12612001270808).
2.3. Statistical analyses
Data were analyzed using analysis of variance (ANOVA)
in GenStat (version 16; VSN International Ltd, HemelTable 1 – Clinical trial interventions
Intervention Composition
Placebo Isomalt
Actazin-L Green kiwifruit powder
Actazin-H Green kiwifruit powder
Gold Gold kiwifruit powderHempstead, UK). Data from the healthy and functionally
constipated cohorts were analyzed separately. Results from
each observation (end of each washout or intervention) were
analyzed as a complete block design, with participant and
participant × phase as blocks and phase (1, 2, 3, or 4) and
intervention (washout, placebo, Actazin-L, Actazin-H, or Gold)
as factors. Washout results were included because of con-
cerns that the placebo treatment may have had prebiotic
effects. Residuals were inspected to ensure that the assump-
tions of ANOVA were met; where necessary, data were log
transformed to stabilize variance. The means presented for
the log-transformed variables have been transformed back to
the original scale. Standard errors of the differences (SEDs)
and t tests were used to calculate P values for the difference
between the washout mean and the means for each
intervention. Cochran Q test [12] was used to compare the
proportion of participants responding to each intervention (ie,
with a rise of at least 1 bowel movement per week over the
preceding washout period). Participants were classified as
either responders (showed a response to at least 1 of the
nonplacebo interventions) or nonresponders.Dose Capsules/day
2400 mg 4 × Placebo
600 mg 1 × Actazin + 3 × placebo
2400 mg 4 × Actazin
2400 mg 4 × Gold
Table 2 – Nutritional information of Actazin and Gold
dietary supplements
Nutrition information (per 100 g) Actazin Gold
Energy, kJ 1435 1420
Protein, g 3.4 3.9
Fat, total, g 3.0 1.8
Saturated, g 0.75 0.34
Unsaturated, g 2.4 1.4
Monounsaturated, g 0.53 <0.10
Polyunsaturated, g 1.8 1.4
Carbohydrate, g 67 71
Sugars, total, g 46 58
Sucrose, g <0.05 <0.05
Glucose, g 21 27
Fructose, g 25 31
Lactose, g <0.05 <0.05
Maltose, g <0.05 <0.05
Dietary fiber, g 16 12
Sodium, mg 13 18
Total polyphenols, mg GAE 900 1100
Actinidin, AUs/g 40700 9100
Abbreviations: GAE, gallic acid equivalents; AUs, activity units.
The substrate used to monitor the activity levels of actinidin
in Actazin and Gold is Nα-Z-L-lysine 4-nitrophenyl ester
hydrochloride (Sigma-Aldrich, Auckland, New Zealand) [10].
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Twenty participants (2 male and 18 female) were recruited into
the healthy cohort. The average age was 38 years (range, 23-56
years), and the average BMI was 23 kg/m2 (range, 19-29 kg/m2).
Nine participants (1 male and 8 female) were recruited into the
functionally constipated cohort. The average age was 44 years
(range, 38-54 years), and the average BMI was 25 kg/m2 (range,
21-29 kg/m2). Table 3 shows the demographic and baseline
characteristics of the study participants.
Of the 20 participants in the healthy cohort, 19 completed the
study. One female participant withdrew for personal reasons,
citing time limitations during the first intervention phase of the
study. All 9 participants in the functionally constipated cohort
completed the study. The reasons for the difficulty in recruit-
ment into the functionally constipated cohort were hard to
determine definitively but included preexisting medical condi-
tions including Crohn disease and diverticulitis, BMI greater
than 30 kg/m2, and current medication regimes that did not fitTable 3 – Baseline demographics of the study participants
Baseline characteristics Health
n 20
Male 2
Female 18
Age in y (mean ± SD) 38 ± 11
Age (range) 23-56
Weight in kg (mean ± SD) 68 ± 13
Weight (range) 47-101
BMI in kg/m2 (mean ± SD) 23 ± 3
BMI (range) 19-29
Abbreviation: SD, standard deviation.the eligibility criteria. A number of participants who identified
themselves as having constipation did not qualify under the
Rome III diagnostic criteria applied in this study. Further
screening ruled out several participants because of high fasting
blood glucose concentrations (>5.7 mmol/L). The length of the
trial, collection of fecal samples, and necessity to abstain from
eating kiwifruit for the 26-week trial durationwere also given as
reasons not to participate.
The participant dietary nutrient intakes recorded at the
beginning and end of the study showed no significant
variations between individuals or during the course of the
study. Compliance for this study was measured by asking
participants to return their unused study product and
counting the remaining supplement capsules. Compliance
was calculated as the percentage of tablets taken from the
original number dispensed. The healthy group of participants
achieved a mean compliance level of 98% ± 9%, whereas the
functionally constipated group reached a mean level of 99% ±
8% over the course of the study.
The blood samples were analyzed to assess the overall
picture of the participant's metabolism by the Chem-20 panel
for the healthy and functionally constipated cohorts; the
results were within the reference ranges (data not shown).
Consumption for 28 days of Actazin at the 2 rates of intake
(Actazin-L and Actazin-H) and Gold was generally well
tolerated, with no serious adverse events reported. There
were no significant effects (P > .05) of consuming the
interventions on the well-being parameters recorded in the
daily questionnaires except for self-reported flatulence,
which was higher with Actazin-H intervention (P = .007) in
the healthy cohort (Table 4).
In the healthy cohort, Actazin-H (P = .014) and Gold (P =
.009) consumption resulted in significant increases in the
mean daily bowel movements, whereas Actazin-L consump-
tion showed a nearly significant increase (P = .060) compared
with the washout (Table 4). No significant differences were
observed in stool form as determined by use of the Bristol
stool scale [11]. In the responder subgroup (selected based on
an increase of 1 bowel movement per week), consumption of
Actazin-L (P = .005), Actazin-H (P < .001), and Gold (P = .001)
resulted in significant increases in daily bowel movements
compared with the washout (Table 4).
In the functionally constipatedcohort, therewerenosignificant
differences between interventions for bowel movements, Bristol
stool scale values, and other well-being parameters (Table 5).y Functionally constipated
9
1
8
44 ± 6
38-54
67 ± 8
53-79
25 ± 2
21-29
Table 4 – Daily bowel movements and well-being parameters in the healthy cohort and responders' subgroup
Mean (95% confidence intervals for difference from washout) ANOVA P values Post hoc P washout vs intervention
Placebo Actazin-L Actazin-H Gold Washout Washout vs
average
of treatments
(1 df)
Treat ent
differ ces
(3 df)
Placebo Actazin-L Actazin-H Gold
Healthy cohort (n = 19)
No. of daily bowel movements a 1.12 (−0.05, 0.13) 1.16 (−0.00, 0.18) 1.19 (0.02, 0.21) 1.20 (0.03, 0.22) 1.08 .002 .918 .377 .060 .014 .009
Bristol stool scale 3.61 (−0.06, 0.44) 3.52 (−0.15, 0.35) 3.61 (−0.06, 0.44) 3.62 (−0.05, 0.45) 3.42 .036 .806 .134 .421 .138 .113
Strain 0.22 (−0.13, 0.02) 0.22 (−0.13, 0.02) 0.24 (−0.11, 0.04) 0.22 (−0.13, 0.02) 0.28 .044 .349 .157 .150 .363 .166
Incomplete evacuation 0.14 (−0.11, 0.04) 0.14 (−0.11, 0.04) 0.13 (−0.13, 0.02) 0.17 (−0.09, 0.06) 0.18 .137 .432 .310 .306 .174 .699
Bloating 0.17 (−0.02, 0.07) 0.15 (−0.04, 0.05) 0.13 (−0.06, 0.03) 0.16 (−0.03, 0.06) 0.14 .497 .490 .223 .757 .631 .503
Flatulence 0.60 (−0.04, 0.08) 0.64 (−0.01, 0.11) 0.67 (0.02, 0.14) 0.64 (−0.01, 0.11) 0.58 .007 .572 .511 .073 .007 .075
Manual maneuvers 0.00 (−0.03, 0.01) 0.02 (−0.01, 0.02) 0.01 (−0.02, 0.01) 0.02 (−0.01, 0.03) 0.01 .860 .339 .247 .637 .343 .234
Laxatives 0.01 (0.00, 0.01) 0.00 (−0.01, 0.00) 0.00 (−0.01, 0.00) 0.00 (−0.01, 0.00) 0.00 .786 .703 .156 .494 .475 .475
Abdominal pain 0.12 (0.01, 0.08) 0.11 (0.00, 0.07) 0.05 (−0.07, 0.01) 0.08 (−0.04, 0.04) 0.08 .339 .375 .021 .083 .103 .980
Responders (n = 14)
No. of daily bowel movements a 1.27 (−0.02, 0.20) 1.35 (0.05, 0.29) 1.39 (0.09, 0.34) 1.38 (0.08, 0.33) 1.18 <.001 .999 .117 .005 <.001 .001
Abbreviation: df, degree of freedom.
The data were averaged for each 4-week dietary interventions (placebo, Actazin-L, Actazin-H, and Gold), and washout is an average of 4 preceding 2-we k washouts. For the ANOVA, the intervention factor
was split into a 1 degree of freedom contrast of washout against the average of the interventions and 3 degrees of freedom term testing the difference ong the interventions. SEDs and t tests were used
to calculate P values for difference between the washout mean and the means for each intervention.
a Data are log transformed for statistical analysis; means presented are back transformed. A subgroup analysis was conducted on the healthy cohort. P rticipants were classified as responders (showed an
increase by at least 1 bowel movement per week over the preceding washout period on at least 1 of the nonplacebo interventions) or nonresponders. ata from the responders' subgroup in healthy (14/19
participants [74%]) cohort were analyzed using ANOVA.
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Table 5 – Daily bowel movements and well-being parameters in the functionally constipated cohort and responders' subgroup
Mean (95% confidence intervals for difference from washout) ANOVA P values Post hoc P washout vs intervention
Placebo Actazin-L Actazin-H Gold Washout Washout vs
average of
treatments
(1 df)
Treatment
differences
(3 df)
Placebo Actazin-L Actazin-H Gold
Functionally constipated cohort (n = 9)
No. of daily bowel movements a 0.96 (−0.14, 0.21) 0.92 (−0.17, 0.18) 0.88 (−0.21, 0.12) 0.99 (−0.11, 0.25) 0.93 .999 .840 .813 .894 .479 .546
Bristol stool scale 3.00 (−0.14, 0.58) 2.93 (−0.21, 0.51) 2.82 (−0.31, 0.40) 2.92 (−0.22, 0.50) 2.78 .210 .215 .223 .396 .799 .437
Strain 0.55 (−0.09, 0.21) 0.43 (−0.21, 0.10) 0.38 (−0.27, 0.04) 0.41 (−0.23, 0.08) 0.49 .321 .527 .433 .462 .147 .305
Incomplete evacuation 0.52 (−0.04, 0.24) 0.40 (−0.15, 0.13) 0.41 (−0.15, 0.14) 0.39 (−0.16, 0.12) 0.41 .720 .671 .155 .852 .957 .749
Bloating 0.09 (−0.12, 0.19) 0.14 (−0.27, 0.05) 0.12 (−0.10, 0.21) 0.14 (−0.36, −0.04) 0.12 .836 .533 .199 .313 .958 .461
Flatulence 0.46 (−0.02, 0.14) 0.32 (−0.01, 0.15) 0.49 (−0.14, 0.02) 0.23 (−0.10, 0.06) 0.43 .254 .228 .667 .158 .474 .015
Manual maneuvers 0.93 (−0.08, 0.02) 0.94 (−0.02, 0.07) 0.81 (−0.05, 0.05) 0.84 (−0.03, 0.07) 0.87 .609 .115 .132 .072 .140 .535
Laxatives 0.01 (−0.01, 0.01) 0.01 (−0.02, 0.01) 0.01 (−0.02, 0.01) 0.02 (−0.01, 0.02) 0.01 .615 .967 .795 .354 .673 .706
Abdominal pain 0.27 (0.02, 0.20) 0.12 (−0.14, 0.05) 0.15 (−0.10, 0.08) 0.12 (−0.14, 0.05) 0.17 .961 .639 .023 .316 .813 .323
Responders (n = 4)
No. of daily bowel movements a 0.99 (−0.18, 0.41) 1.18 (−0.03, 0.66) 1.03 (−0.15, 0.46) 1.10 (−0.10, 0.56) 0.92 .086 .915 .584 .087 .399 .197
Abbreviation: df, degree of freedom.
The data were averaged for each 4-week dietary intervention (placebo, Actazin-L, Actazin-H, and Gold), and washout is an average of 4 preceding 2-week washouts. For the ANOVA, the intervention
factor was split into a 1 degree of freedom contrast of washout against the average of the interventions and 3 degrees of freedom term testing the difference among the interventions. SEDs and t tests
were used to calculate P values for difference between the washout mean and the means for each intervention.
a Data log transformed for statistical analysis; means presented are back transformed. A subgroup analysis was conducted on the functionally constipated cohort. Participants were classified as responders
(showed an increase by at least 1 bowel movement per week over the preceding washout period on at least 1 of the nonplacebo interventions) or nonresponders. Data from the responders' subgroup in
functionally constipated (4/9 participants [45%]) cohort were analyzed using ANOVA.
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407N U T R I T I O N R E S E A R C H 3 5 ( 2 0 1 5 ) 4 0 1 – 4 0 8The subgroup analysis of responders also showed no significant
differences (P = .086) between interventions and washout for the
numbers of bowel movements.4. Discussion
This study demonstrated that the consumption of Actazin
and Gold increased stool frequency but did not affect stool
form as measured by the Bristol stool score or the other
measures of gastrointestinal comfort. An increase of greater
than 1 bowel movement per week in a symptomatic popula-
tion is considered a clinically meaningful magnitude of effect
[13]. The consumption of Actazin and Gold demonstrated this
degree of efficacy in the healthy responders in the present
study. This suggests that kiwifruit bioactive components
present in these products (ie, fiber; polyphenols; and the
enzyme, actinidin) [14] improved regularity and laxation
without affecting the stool form. No prior studies have
investigated the effect of fresh gold kiwifruit or its products
on laxation in humans. Whereas, the beneficial effects of
green kiwifruit have been investigated in several clinical
studies demonstrating improved laxation in healthy individ-
uals [6,7] and in patients with irritable bowel syndrome with
constipation [8]. In a clinical study with freeze-dried green
kiwifruit powder (5.5 g/day), the product was also well
tolerated, and the numbers of bowel movements were
significantly increased after 28 days [15]. It remains unclear
which of the bioactive components or their combinations in
kiwifruit are influencing laxation.
In the individuals with functional constipation (n = 9), the
dietary interventions did not significantly increase the frequen-
cy of bowel movements compared with the washout. This is
likely to be due to the small sample size resulting in inadequate
statistical power to detect significant differences. It should be
noted that, in the functionally constipated responders group,
therewas a numerical increase of bowelmovements compared
with thewashout for theActazinandGold interventions. This is
supported by a meta-analysis of randomized controlled trials
showing that additional dietary fiber consumption increases
stool frequency in patients with constipation; but stool
consistency, laxative use, and painful defecation were not
improved [16]; and an earlier study reported similar effects of
prebiotic xylooligosaccharides in healthy adults [17].
In the present study, isomalt was the placebo interven-
tion. Isomalt is an equimolar mixture of 2 disaccharides,
each composed of 2 sugars: glucose and mannitol
(α-D-glucopyranosido-1,6-mannitol) and glucose and sorbitol
(α-D-glucopyranosido-1,6-sorbitol), respectively. In some
studies, this product has been shown to have a prebiotic
effect by increasing bifidobacteria population and the pro-
duction of butyrate [18]; this prebiotic response was achieved
after feeding 30 g of isomalt daily to participants. In the
current study, the maximum amount of isomalt given at any
one time was 2.4 g, which is 12 times lower than the amount
used by Gostner et al [18] and is unlikely to have led to
significant osmotic and fermentative effects.
Based on the power calculations [19], n = 25 individualswould
be necessary to detect a difference of 1.6/week in stool frequency
with 80% power with a P = .05 1-tailed test. Therefore, the mainlimitation of this study was the low numbers of participants
recruited into the functionally constipated cohort. In addition,
the daily dietary intakewas notmonitored closely during this 26-
week study, which means that changes in diet made by the
participants could have been wide and varied, with the potential
to affect bowel health. We also note most of the trial population
were female and were not monitored for their menstrual cycle
over the course of this study; this may also have had an impact
on the measures of bowel health carried out in this study.
Further studies are required to confirm the results of this study
in a larger group of participants to overcome some of the
limitations, including the low recruitment into the functionally
constipated group and the minimal monitoring of dietary intake
during the interventions. The evaluation of other digestive health
markers such as immune function and microbiota composition
could provide further evidence for the roles of Actazin andGold in
enhancing gastrointestinal comfort and health beyond laxation.
Overall, the intake of Actazin (600 and 2400 mg/day) and
Gold (2400 mg/day) was well tolerated, and Actazin-H and Gold
significantly increased daily bowel movements by more than 1
bowel movement per week. The novel finding of this studywas
the influence of Gold in promoting laxation. These kiwifruit-
derived supplements demonstrated a clinically meaningful
increase in bowel movements in healthy individuals.Acknowledgment
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